Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview

1127studies shown

Showing 51-75 of 1,127

RecruitingNCT05649800

Vascular mEchanisms in, Stroke, dePression, dementiA, and deliRum: The VESPAR Project

This study is recruiting. It focuses on depression and currently lists participation information in the United Kingdom.

DepressionOtherOver 65 Years

Countries: United Kingdom
Sponsor: University of Leicester
Condition: Depression

View study

RecruitingNCT06604104

Visual Frailty in Ageing

This study is recruiting. It focuses on anxiety and currently lists participation information in the United Kingdom.

AnxietyOtherOver 60 Years

Countries: United Kingdom
Sponsor: University of Edinburgh
Condition: Anxiety

View study

Not Yet RecruitingNCT07232472

Wearable-Based Study of Depression and Sleep in Older Adults

This study is not yet recruiting. It focuses on depression and currently lists study information in the United Kingdom.

DepressionOtherOver 60 Years

Countries: United Kingdom
Sponsor: China Medical University Hospital
Condition: Depression

View study

RecruitingNCT05862636

Who Fares Best With Mindfulness Meditation

This study is recruiting. It focuses on depression and currently lists participation information in Belgium and the United Kingdom.

DepressionBehavioralOver 18 Years

Countries: Belgium, United Kingdom
Sponsor: Prof. dr. Filip Raes
Condition: Depression

View study

Active Not RecruitingNCT05905003

AMP SCZ® Observational Study: PREDICT-DPACC

This study is active but not recruiting. It focuses on schizophrenia and currently lists study information in Australia, Canada, Chile, China, Denmark, Germany, Italy, Singapore, South Korea, Spain, Switzerland, the United Kingdom, and the United States.

SchizophreniaOtherFrom 12 Years to 30 Years

Countries: Australia, Canada, Chile, China, Denmark, Germany, Italy, Singapore, South Korea, Spain, Switzerland, United Kingdom, United States
Sponsor: Brigham and Women's Hospital
Condition: Schizophrenia

View study

RecruitingNCT06687694

Immune Mechanisms of Antipsychotic Treatment Response

This study is recruiting. It focuses on schizophrenia and currently lists participation information in the United Kingdom.

SchizophreniaOtherFrom 18 Years to 65 Years

Countries: United Kingdom
Sponsor: King's College London
Condition: Schizophrenia

View study

RecruitingNCT07201909

CALM Study: Can A Prebiotic Fibre bLend Improve Stress, Mood, and Anxiety?

This study is recruiting. It focuses on anxiety and currently lists participation information in the United Kingdom.

AnxietyOtherFrom 18 Years to 50 Years

Countries: United Kingdom
Sponsor: Myota GmbH
Condition: Anxiety

View study

Not Yet RecruitingNCT07175454

IBDminds - Mapping the Influence of aNxiety and DepreSsion on IBD

This study is not yet recruiting. It focuses on anxiety and currently lists study information in the United Kingdom.

AnxietyOtherOver 16 Years

Countries: United Kingdom
Sponsor: The Royal Wolverhampton Hospitals NHS Trust
Condition: Anxiety

View study

Not Yet RecruitingNCT07470437

The Mouth Matters in Mental Health Trial -2

This study is not yet recruiting. It focuses on schizophrenia and currently lists study information in the United Kingdom.

SchizophreniaOtherOver 18 Years

Countries: United Kingdom
Sponsor: Lancashire and South Cumbria NHS Foundation Trust
Condition: Schizophrenia

View study

RecruitingNCT05304767

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

This study is recruiting. It focuses on schizophrenia and currently lists participation information in Bulgaria, Czech Republic, India, Japan, Poland, Romania, Serbia, the United Kingdom, and the United States.

SchizophreniaOtherFrom 18 Years to 65 Years

Countries: Bulgaria, Czech Republic, India, Japan, Poland, Romania, Serbia, United Kingdom, United States
Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition: Schizophrenia

View study

RecruitingNCT07288333

Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia

This study is recruiting. It focuses on schizophrenia and currently lists participation information in the United Kingdom.

SchizophreniaOtherFrom 18 Years to 55 Years

Countries: United Kingdom
Sponsor: Neurocrine Biosciences
Condition: Schizophrenia

View study

Not Yet RecruitingNCT07434973

Stratification and Treatment in Early Psychosis Study - PROMOTE

This study is not yet recruiting. It focuses on schizophrenia and currently lists study information in Austria, Canada, Finland, Germany, Greece, Italy, the Netherlands, Spain, Switzerland, and the United Kingdom.

SchizophreniaOtherFrom 12 Years to 35 Years

Countries: Austria, Canada, Finland, Germany, Greece, Italy, Netherlands, Spain, Switzerland, United Kingdom
Sponsor: University of Oxford
Condition: Schizophrenia

View study

RecruitingNCT07419321

Social Isolation and Aging in Schizophrenia

This study is recruiting. It focuses on schizophrenia and currently lists participation information in the Netherlands, Spain, the United Kingdom, and the United States.

SchizophreniaOtherFrom 40 Years to 70 Years

Countries: Netherlands, Spain, United Kingdom, United States
Sponsor: Icahn School of Medicine at Mount Sinai
Condition: Schizophrenia

View study

RecruitingNCT06957808

Investigating the Effect of Diroximel Fumarate on Glutathione in Schizophrenia

This study is recruiting. It focuses on schizophrenia and currently lists participation information in the United Kingdom.

SchizophreniaOtherFrom 18 Years to 65 Years

Countries: United Kingdom
Sponsor: King's College London
Condition: Schizophrenia

View study

RecruitingNCT05656469

Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders

This study is recruiting. It focuses on anxiety and currently lists participation information in Germany, the Netherlands, Romania, Serbia, Spain, the United Kingdom, and the United States.

AnxietyOtherFrom 16 Years to 65 Years

Countries: Germany, Netherlands, Romania, Serbia, Spain, United Kingdom, United States
Sponsor: Maastricht University Medical Center
Condition: Anxiety

View study

RecruitingNCT06568081

SloMo2: Implementation, Effectiveness, and Cost-effectiveness Study

This study is recruiting. It focuses on schizophrenia and currently lists participation information in the United Kingdom.

SchizophreniaOtherOver 18 Years

Countries: United Kingdom
Sponsor: King's College London
Condition: Schizophrenia

View study

Not Yet RecruitingNCT07326124

Stratification and Treatment in Early Psychosis Study -ASSIST

This study is not yet recruiting. It focuses on schizophrenia and currently lists study information in Germany, Greece, Israel, Italy, the Netherlands, Spain, Switzerland, and the United Kingdom.

SchizophreniaOtherFrom 16 Years to 50 Years

Countries: Germany, Greece, Israel, Italy, Netherlands, Spain, Switzerland, United Kingdom
Sponsor: University of Oxford
Condition: Schizophrenia

View study

Not Yet RecruitingNCT06778564

Stratification and Treatment in Early Psychosis Study - ENHANCE

This study is not yet recruiting. It focuses on schizophrenia and currently lists study information in Austria, Germany, Greece, Israel, Italy, the Netherlands, Spain, Switzerland, and the United Kingdom.

SchizophreniaOtherFrom 16 Years to 40 Years

Countries: Austria, Germany, Greece, Israel, Italy, Netherlands, Spain, Switzerland, United Kingdom
Sponsor: University of Oxford
Condition: Schizophrenia

View study

Not Yet RecruitingNCT07252206

A Case Series of Culturally-adapted CBTp for Black People in the UK

This study is not yet recruiting. It focuses on schizophrenia and currently lists study information in the United Kingdom.

SchizophreniaOtherOver 16 Years

Countries: United Kingdom
Sponsor: University of Manchester
Condition: Schizophrenia

View study

Not Yet RecruitingNCT07245212

Testing the Efficacy of the Cannabis Clinic for Patients With Psychosis (CCP) Intervention for Cannabis Use Reduction/Cessation in Patients With First Episode Psychosis (FEP)

This study is not yet recruiting. It focuses on schizophrenia and currently lists study information in the United Kingdom.

SchizophreniaOtherFrom 18 Years to 65 Years

Countries: United Kingdom
Sponsor: King's College London
Condition: Schizophrenia

View study

RecruitingNCT07196423

Early Psychosis: Investigating Cognition

This study is recruiting. It focuses on schizophrenia and currently lists participation information in the United Kingdom.

SchizophreniaOtherFrom 18 Years to 55 Years

Countries: United Kingdom
Sponsor: University of Nottingham
Condition: Schizophrenia

View study

RecruitingNCT05958875

The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

This study is recruiting. It focuses on schizophrenia and currently lists participation information in Austria, Germany, Italy, Spain, and the United Kingdom.

SchizophreniaOtherFrom 18 Years to 70 Years

Countries: Austria, Germany, Italy, Spain, United Kingdom
Sponsor: Dr. Inge Winter
Condition: Schizophrenia

View study

RecruitingNCT06236048

Energetics and Glutamate in Schizophrenia

This study is recruiting. It focuses on schizophrenia and currently lists participation information in the United Kingdom.

SchizophreniaOtherFrom 18 Years to 65 Years

Countries: United Kingdom
Sponsor: King's College London
Condition: Schizophrenia

View study

RecruitingNCT06126224

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

This study is recruiting. It focuses on schizophrenia and currently lists participation information in Belgium, Canada, Chile, China, Greece, Hungary, Mexico, Peru, Poland, South Korea, Switzerland, Turkey, the United Kingdom, and the United States.

SchizophreniaOtherFrom 55 Years to 90 Years

Countries: Belgium, Canada, Chile, China, Greece, Hungary, Mexico, Peru, Poland, South Korea, Switzerland, Turkey, United Kingdom, United States
Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition: Schizophrenia

View study

RecruitingNCT05980949

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

This study is recruiting. It focuses on schizophrenia and currently lists participation information in Argentina, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czech Republic, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Mexico, Peru, Poland, Portugal, the United States, Romania, Serbia, Slovakia, South Korea, Spain, Turkey, Ukraine, and the United Kingdom.

SchizophreniaOtherFrom 55 Years to 90 Years

Countries: Argentina, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czech Republic, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Mexico, Peru, Poland, Portugal, United States, Romania, Serbia, Slovakia, South Korea, Spain, Turkey, Ukraine, United Kingdom
Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition: Schizophrenia

View study